NGM Biopharmaceuticals Inc (NASDAQ:NGM)

5.38
Delayed Data
As of Nov 25
 +0.045 / +0.84%
Today’s Change
2.92
Today|||52-Week Range
19.14
-69.65%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$436.4M

Company Description

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.

Contact Information

NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
South San Francisco California 94080-7014
P:(650) 243-5555
Investor Relations:

Employees

Shareholders

Individual stakeholders33.99%
Other institutional26.12%
Mutual fund holders18.58%

Top Executives

David J. WoodhouseChief Executive Officer & Director
Siobhan Nolan ManginiPresident & Chief Financial Officer
Jin Long ChenDirector & Chief Scientific Officer
Hui TianVice President-Research
Marc LearnedVice President-Research Operations